SCHEMBL5557693

SCHEMBL5557693

O=C(c1cc(C(F)(F)F)cc(C(F)(F)F)c1)N1CCC2(CC1)C(=O)NCN2C(=O)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 8/20 0.55
TSHR P16473 7/20 0.55
USP2 O75604 9/20 0.54
HSD17B10 Q99714 3/20 0.54
CYP2C9 P11712 5/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
HIF1A Q16665 3/20 0.50
CYP2D6 P10635 3/20 0.50
ALDH1A1 P00352 2/20 0.50
HPGD P15428 1/20 0.50
ALOX15 P16050 1/20 0.50
MAPK1 P28482 1/20 0.50
TACR1 P25103 1/20 0.48
CYP1A2 P05177 3/20 0.48
CYP2C19 P33261 1/20 0.48
OPRD1 P41143 1/20 0.46
MGLL Q99685 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5553371 0.85 CYP3A4 (0.61) CYP3A4TSHRUSP2HSD17B10CYP2C9
SCHEMBL5553322 0.82 USP2 (0.63) CYP3A4TSHRUSP2HSD17B10CYP2C9
SCHEMBL5559624 0.81 CYP3A4 (0.51) CYP3A4TSHRUSP2HSD17B10CYP2C9
SCHEMBL5557778 0.80 CYP3A4 (0.49) CYP3A4TSHRUSP2HSD17B10CYP2C9
SCHEMBL5557913 0.80 PLD2 (0.55) CYP3A4TSHRUSP2HSD17B10HIF1A
SCHEMBL5558262 0.80 USP2 (0.49) CYP3A4TSHRUSP2HSD17B10CYP2C9
SCHEMBL5553130 0.78 CYP3A4 (0.64) CYP3A4TSHRUSP2HSD17B10CYP2C9
SCHEMBL5557707 0.78 USP2 (0.53) CYP3A4TSHRUSP2HSD17B10CYP2C9
SCHEMBL5557466 0.77 USP2 (0.55) CYP3A4TSHRUSP2HSD17B10CYP2C9
SCHEMBL5557537 0.77 USP2 (0.52) CYP3A4TSHRUSP2HSD17B10CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6482829-B2 CENTRAL NERVOUS SYSTEM DISORDERS; HEEADACHES, ANTIINFLAMMATORY AGENTS HOFFMANN-LA ROCHE INC. 2002-11-19 US claimed
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor F. HOFFMANN-LA ROCHE AG (CH) 2002-01-17 US claimed
EP-1292596-B1 1,3,8-TRIAZA-SPIRO¬4,5 DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2007-12-19 EP disclosed
EP-1292596-A1 1,3,8-TRIAZA-SPIRO[4,5]DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-03-19 EP disclosed
US-6482829-B2 CENTRAL NERVOUS SYSTEM DISORDERS; HEEADACHES, ANTIINFLAMMATORY AGENTS HOFFMANN-LA ROCHE INC. 2002-11-19 US disclosed
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor F. HOFFMANN-LA ROCHE AG (CH) 2002-01-17 US disclosed
WO-2001094346-A1 1,3,8-TRIAZA-SPIRO'4,5!DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006932-A1 Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor TACR1, TACR2, NPR1 CYP3A4 3223/4885TSHR 232/4885USP2 3849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.